Table S9 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation

NIAID Data Ecosystem2026-05-02 收录

数据链接：

https://figshare.com/articles/dataset/Table_S9_from_Synergistic_Effects_of_PARP_Inhibition_and_Cholesterol_Biosynthesis_Pathway_Modulation/28672585 数据链接链接失效反馈

官方服务：

资源简介：

Expression proteomic signature

创建时间：

2024-09-16

Inhibition of CBP synergizes with the RNA-dependent mechanisms of azacitidine by limiting protein synthesis. Inhibition of CBP synergizes with the RNA-dependent mechanisms of azacitidine by limiting protein synthesis

癌症表观遗传治疗

药物协同机制

The nucleotide analogue azacitidine interferes with RNA and DNA metabolism and is currently the best treatment option for a subset of patients with high-risk myelodysplastic syndromes. However, only h

NIAID Data Ecosystem50

HDAC and Proteasome Inhibitors Synergize to Activate Pro-Apoptotic Factors in Synovial Sarcoma

滑膜肉瘤治疗

药物协同机制

Conventional cytotoxic therapies for synovial sarcoma provide limited benefit, and no drugs specifically targeting its driving SS18-SSX fusion oncoprotein are currently available. Patients remain at h

NIAID Data Ecosystem40

Ribonucleotide reductase inhibitors suppress SAMHD1 ara-CTPase activity enhancing ara-C efficacy

化疗联合治疗

药物协同机制

The deoxycytidine analogue cytarabine (ara-C) remains the backbone treatment of acute myeloid leukaemia (AML) as well as other haematological and lymphoid malignancies, but must be combined with other

NIAID Data Ecosystem30

Withaferin A Synergizes the Therapeutic Effect of Doxorubicin through ROS-Mediated Autophagy in Ovarian Cancer

卵巢癌联合化疗

药物协同机制

Application of doxorubicin (Dox) for the treatment of cancer is restricted due to its severe side effects. We used combination strategy by combining doxorubicin (Dox) with withaferin A (WFA) to minimi

NIAID Data Ecosystem50

BET bromodomain inhibitors synergize with ATR inhibitors to induce DNA damage, apoptosis, senescence-associated secretory pathway and ER stress in Myc- induced lymphoma cells. Mus musculus

淋巴瘤靶向治疗

药物协同机制

The aim of the project was to determine the expression profiles of murine Myc-driven lymphpma cells (Lambda-820) treated with vehicle (DMSO, 1:1000), a BET inhibitor (RVX2135), an ATR inhibitor (VE-82

NIAID Data Ecosystem40

Table S9 from Synergistic Effects of PARP Inhibition and Cholesterol Biosynthesis Pathway Modulation

资源简介：

相关数据集